Shares of Evofem Biosciences Inc (NASDAQ:EVFM) have been given a consensus recommendation of “Buy” by the seven analysts that are currently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $10.75.
A number of research analysts have weighed in on EVFM shares. Cantor Fitzgerald reiterated a “buy” rating and set a $9.00 price objective on shares of Evofem Biosciences in a research report on Monday, March 4th. Zacks Investment Research cut shares of Evofem Biosciences from a “hold” rating to a “sell” rating in a research report on Wednesday, February 6th. HC Wainwright reiterated a “buy” rating on shares of Evofem Biosciences in a research report on Monday, April 15th. Finally, Oppenheimer boosted their price objective on shares of Evofem Biosciences from $9.00 to $11.00 and gave the company an “outperform” rating in a research report on Friday, April 12th.
EVFM stock traded up $0.20 during mid-day trading on Friday, reaching $5.41. 63,167 shares of the stock traded hands, compared to its average volume of 54,148. Evofem Biosciences has a one year low of $1.79 and a one year high of $7.24. The stock has a market capitalization of $191.34 million, a price-to-earnings ratio of -0.94 and a beta of 1.58.
Several hedge funds and other institutional investors have recently bought and sold shares of EVFM. Vanguard Group Inc bought a new position in shares of Evofem Biosciences in the third quarter worth about $879,000. Vanguard Group Inc. bought a new position in shares of Evofem Biosciences in the third quarter worth about $879,000. Geode Capital Management LLC grew its holdings in shares of Evofem Biosciences by 115.2% in the fourth quarter. Geode Capital Management LLC now owns 73,650 shares of the biotechnology company’s stock worth $308,000 after purchasing an additional 39,425 shares during the last quarter. Northern Trust Corp bought a new position in shares of Evofem Biosciences in the first quarter worth about $120,000. Finally, BlueCrest Capital Management Ltd bought a new position in shares of Evofem Biosciences in the first quarter worth about $84,000. Hedge funds and other institutional investors own 63.91% of the company’s stock.
Evofem Biosciences Company Profile
Evofem Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products. Its lead product candidate is Amphora, a non-hormonal woman-controlled vaginal gel, which is in Phase 3 clinical trial for the prevention of pregnancy; and in Phase 2b trial for the prevention of chlamydia and gonorrhea in women.
Featured Article: Technical Analysis
Receive News & Ratings for Evofem Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evofem Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.